Structure-function and regulation of ADAMTS-13 protease.

Area of Science:

• Biochemistry
• Hematology
• Molecular Biology

Background:

• ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin type 1 repeats, member 13) is a plasma enzyme that cleaves von Willebrand factor (VWF).
• Severe ADAMTS-13 deficiency causes thrombotic thrombocytopenic purpura (TTP), while partial deficiencies are linked to myocardial infarction, cerebral infarction, pre-eclampsia, and malaria.
• Adamts13(-/-) mice exhibit exacerbated inflammatory responses, ischemia/reperfusion injury, and atherosclerosis.

Purpose of the Study:

• To elucidate the structure-function relationship of ADAMTS-13 in VWF proteolysis.
• To investigate the role of FVIII and platelets in regulating ADAMTS-13 activity.
• To identify therapeutic targets for acquired TTP and other thrombotic disorders.

Main Methods:

• Structure-function analysis of ADAMTS-13 domains.
• In vitro and in vivo studies using knockout mice and assays involving FVIII and platelets.
• Autoantibody mapping in patients with acquired TTP.

Main Results:

• The N-terminal MDTCS domain of ADAMTS-13 is essential for VWF cleavage and thrombosis attenuation.
• The distal TSP1 2-8 repeats and CUB domains may act as a disulfide bond reductase, preventing ultra-large VWF string elongation and inhibiting platelet aggregation.
• FVIII and platelets significantly accelerate VWF proteolysis by ADAMTS-13, acting as physiological cofactors.
• An ADAMTS-13 variant with enhanced activity and reduced autoantibody inhibition was identified.

Conclusions:

• ADAMTS-13 plays a critical role in VWF proteolysis, with distinct domains mediating different functions.
• FVIII and platelets are key regulators of ADAMTS-13 activity under flow conditions.
• These findings offer insights into TTP pathogenesis and potential therapeutic strategies for thrombotic disorders.